- Home
- MBRX vs DHAI Comparison
MBRX vs DHAI Comparison
Compare MBRX & DHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- DHAI
- Stock Information
- Founded
- MBRX 2015
- DHAI 2007
- Country
- MBRX United States
- DHAI United States
- Employees
- MBRX N/A
- DHAI N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- DHAI
- Sector
- MBRX Health Care
- DHAI
- Exchange
- MBRX Nasdaq
- DHAI NYSE
- Market Cap
- MBRX 12.9M
- DHAI 10.5M
- IPO Year
- MBRX 2016
- DHAI N/A
- Fundamental
- Price
- MBRX $0.32
- DHAI $0.25
- Analyst Decision
- MBRX Strong Buy
- DHAI
- Analyst Count
- MBRX 3
- DHAI 0
- Target Price
- MBRX $5.33
- DHAI N/A
- AVG Volume (30 Days)
- MBRX 5.5M
- DHAI 6.2M
- Earning Date
- MBRX 08-13-2025
- DHAI 08-18-2025
- Dividend Yield
- MBRX N/A
- DHAI N/A
- EPS Growth
- MBRX N/A
- DHAI N/A
- EPS
- MBRX N/A
- DHAI N/A
- Revenue
- MBRX N/A
- DHAI $69,573,000.00
- Revenue This Year
- MBRX N/A
- DHAI N/A
- Revenue Next Year
- MBRX N/A
- DHAI N/A
- P/E Ratio
- MBRX N/A
- DHAI N/A
- Revenue Growth
- MBRX N/A
- DHAI 5.40
- 52 Week Low
- MBRX $0.25
- DHAI $0.12
- 52 Week High
- MBRX $4.71
- DHAI $3.67
- Technical
- Relative Strength Index (RSI)
- MBRX 23.94
- DHAI 56.22
- Support Level
- MBRX $0.29
- DHAI $0.24
- Resistance Level
- MBRX $0.42
- DHAI $0.30
- Average True Range (ATR)
- MBRX 0.05
- DHAI 0.04
- MACD
- MBRX -0.02
- DHAI 0.00
- Stochastic Oscillator
- MBRX 10.82
- DHAI 46.14
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.